Differential regulation of cardiac angiotensin converting enzyme binding sites and AT1 receptor density in the failing human heart

Circulation

Volumn 98, Issue 17, 1998, Pages 1735-1741

  Zisman, Lawrence S ^a,b   Asano, Koji ^a   Dutcher, Darrin L ^a   Ferdensi, Anthony ^a   Robertson, Alastair D ^a   Jenkin, Matthew ^a   Bush, Erik W ^a   Bohlmeyer, Teresa ^a   Perryman, M Benjamin ^a   Bristow, Michael R ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiotensin; Cardiomyopathy; Pulmonary heart disease

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ADENYLATE CYCLASE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRILAT; IODINE 125; LOSARTAN; RAMIPRILAT; SARALASIN; TRITIUM;

ADULT; ARTICLE; BINDING SITE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FAILURE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RECEPTOR DENSITY;

EID: 0032573027     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.17.1735     Document Type: Article

References (23)

1. Cleland JGF, Dargie HJ, Hodsman GP, Ball SG, Robertson JIS, Morton JJ, East BW, Robertson I, Murray GD, Gillen G. Captopril in heart failure: a double blind controlled trial. Br Heart J. 1984;52:530-535.
2. Pacher R, Globits S, Bergler-Klein J, Teufelsbauer H, Wutte M, Baumgartner W, Ogris E, Glogar D. Clinical and neurohumoral response of patients with severe congestive heart failure treated with two different captopril dosages. Eur Heart J. 1993;14:273-278.
3. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
4. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman B, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic-congestive heart failure. N Engl J Med. 1991;325:303-310.
5. Dzau V, Re R. Tissue angiotensin system in cardiovascular medicine: a paradigm shift? Circulation. 1994;89:493-498.
6. Gilbert EM, Sandoval A, Larrabee P, Renlund DG, O'Connell JB, Bristow MR. Lisinopril lowers cardiac adrenergic drive and increases β-receptor density in the failing human heart. Circulation. 1993;88:472-480.
7. Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, Horiuchi M, Pratt RE. Dzau VJ. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the ATI receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci USA. 1995;92: 10663-10667.
8. 1-receptor subtype in failing human ventricular myocardium. Circulation. 1997;95:1193-1200.
9. 2 angiotensin receptor gene expression in human heart failure. Circulation. 1997;95:1201-1206.
10. Studer R, Reinecke H, Muller B, Holtz J, Just H, Drexler H. Increased angiotensin-I converting enzyme gene expression in the failing human heart. J Clin Invest. 1994;94:301-310.
11. Bristow MR, Minobe W, Rasmussen R, Larrabee P, Skerl L, Klein JW, Anderson FL, Murray J, Mestroni L, Karwande SV, Fowler M, Ginsburg R. B-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest. 1992;89:803-815.
12. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Jamieson S, Stinson EB. β1 and β2 adrenergic receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective β1 receptor down-regulation in heart failure. Circ Res. 1986;59:297-309.
13. Vago T, Bevilacqua M, Conci F, Baldi G, Ongini E, Chebat E, Monopoli A, Norbiato G. Angiotensin converting enzyme binding sites in human heart and lung: comparison with rat tissues. Br J Pharmacol. 1992;107:821-825.
14. Wei L, Alhenc-Gelas F, Corvol P, Clauser E. The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. J Biol Chem. 1991;266:9002-9008.
15. Zisman LS, Abraham WT, Meixell GE, Vamvakias BN, Quaife RA, Lowes BD, Roden RL, Peacock SJ, Groves BM, Raynolds MV, Bristow MR, Perryman MB. Angiotensin II formation in the intact human heart: predominance of the angiotensin-converting enzyme pathway. J Clin Invest. 1995;95:1490-1498.
16. Danser AHJ, van Kesteren CAM, Bas WA, Tavenier M, Derkx FHM, Saxena PR, Schalekamp MADH. Prorenin. renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts: evidence for renin binding. Circulation. 1997;96:220-226.
17. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res. 1990;66:883-890.
18. Wolny A, Clozel J, Rein J, Mory P, Vogt P, Turino M, Kiowski W, Fischli W. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res. 1997;80:219-227.
19. Lassegue B, Alexander RW, Nickenig G, Clark M, Murphy TJ, Griendling KK. Angiotensin II down-regulates the vascular smooth muscle AT1 receptor by transcriptional and post-transcriptional mechanisms: evidence for homologous and heterologous regulation. Mol Pharmacol. 1995;48:601-609.
20. Duggan J, Kilfeather S, O'Brien E, O'Malley K, Nussberger J. Effects of aging and hypertension on plasma angiotensin II and platelet angiotensin II receptor density. Am J Hypertens. 1992;5:687-693.
21. Cai G, Gurdal H, Seasholtz T, Johnson M, Age-related changes in angiotensin II-stimulated vascular contraction and inositol phosphate accumulation in Fischer 344 rats. Mech Ageing Dev. 1994;76:125-133.
22. Falkenhahn M, Franke F, MariaBohle R, Zhu Y, Stauss HM, Bachmann S, Danilov S, Unger T. Cellular distribution of angiotensin-converting enzyme after myocardial infarction. Hypertension. 1995;25:219-226.
23. Hokimoto S, Yasue H, Fujimoto K, Yamamoto H, Nakao K, Kaikita K, Sakata R, Miyamoto E. Expression of angiotensin-converting enzyme in remaining viable myocytes of human ventricles after myocardial infarction. Circulation. 1996;94:1513-1518.